Mode
Text Size
Log in / Sign up
Phase 2 N=140 Randomized Double-blind Treatment

Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence

Venous Hypertension Ulcers · Venous Stasis Ulcer · Venous Ulcer · Venous Insufficiency · Leg Ulcer

Enrolled (actual)
140
Serious AEs
9.3%
Results posted
Jun 2021
Primary outcome: Primary: Number of Participants With Ulcer Recurrence — 6; 3; 11; 5 participants — p=0.091

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Cooling gel pack (Device); Cooling cotton pack (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Mar 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Ulcer Recurrence
6; 3; 11; 5 0.091
PRIMARY
Change in Pain (Worst Pain, Least Pain, Pain Now)
0.85; 0.4; 0; -1.0; 0.3; 0
PRIMARY
Differences in Step Counts
17295; 14234; 13232; 15479
PRIMARY
Change in Mean Scores on Quality of Life Measured With the VEINES QOL/Sym Questionnaire
13.8; -4.8; 24.2; -4.3
PRIMARY
Changes in Severity and Intensity Pain Scores Measured With the Brief Pain Inventory
-0.5; -0.2; 0; 0.4; -0.4; -0.5
PRIMARY
Change in METS Minutes Engaging in Physical Activity Measured With The International Physical Activity Questionnaire
73; 799; 1921; 225
PRIMARY
Time Spent in Minutes Engaging in Physical Activities
1420; 2523; 135; 157
SECONDARY
Participant Adherence to the Study Protocol
106; 82
SECONDARY
Number of Participants Indicating 'Yes' or 'Easy' on Study Instructions, Thermometer Use, Completing Logs, Performing Treatment, Helpfulness
36; 34; 26; 25; 36; 32
SECONDARY
Knowledge Questionnaire of Study Instructions
11.7; 11.9; 11.8; 11.9

Summary

The goal of this study is to test MUSTCOOL, a home-based self-monitoring and self-management ulcer prevention intervention for patients with newly healed chronic venous leg and diabetic foot ulcers. Almost 90% of ulcers recur within 3 months of healing. During the six-month randomized clinic trial, skin temperature will be monitored daily, a maintenance dose of cooling gel pack or placebo will be applied three times weekly to the affected skin, and a bolus dose of cooling will be applied for 5 consecutive days if skin temperature becomes elevated. Outcomes on the incidence of leg ulcer recurrence, pain, physical activity and quality of life will be measured.

Eligibility Criteria

Inclusion Criteria

  • Newly healed leg or diabetic foot ulcer within past 7 - 14 days
  • Ankle brachial index 0.8- 1.3mmHg (rule out absence of arterial disease)
  • Willing to wear compression stockings and appropriate footwear
  • Working freezer

Exclusion Criteria

  • Open leg or foot ulcers
  • Cognitive impairment: unable to recall 2 or more words or draw clock Mini-Cog™ for cognitive impairment
  • Chronic inflammatory or vascular conditions where blood flow of skin may be impaired such as Lupus erythematosus, Raynaud's, scleroderma, end stage renal disease, chronic regional pain syndrome, multiple sclerosis, hypersensitivity to cold, on chemotherapy
  • Unable to preform required protocol activities without assistance (return demonstration to study staff)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02626156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search